Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Apr 25 2017

Hadassah Performs World First Two-Robot Repair of Complex Spinal Break

Suffering six broken vertebrae and leg fractures in two places, Mr. Schwartz was brought to the underground hybrid operating room in Hadassah Hospital Ein Kerem’s Sarah Wetsman Davidson Hospital Tower. “In the hybrid room are two robots,” explains Prof. Meir Liebergall, head of Hadassah’s Orthopedic Department. “The more innovative of the two is the Zeego...

READ MORE ›
alt_text

Monday, Apr 24 2017

Hadassah Surgeon Saves Hands of Border Guards

It was cold and dark outside the Lions Gate of the Old City at 4 am on March 13, the day on which Jerusalem citizens were celebrating Purim.

READ MORE ›
alt_text

Monday, Apr 24 2017

Hadassah’s New Home Away from Home for Parents with Ill Children

Hadassah Hospital Mount Scopus now houses Israel’s first Pediatric Palliative and Supportive Care Center, a home away from home for parents and their children with chronic or terminal diseases.

READ MORE ›
alt_text

Thursday, Apr 13 2017

Mom Follows in Son’s Footsteps
as Kidney Donor

Meir Holtz donated his kidney to a stranger, not knowing that two months later his mom would follow in his footsteps.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More